Results 281 to 290 of about 145,356 (331)

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings   +6 more
wiley   +1 more source

Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a). [PDF]

open access: yesAtheroscler Plus
Koutsogianni AD   +6 more
europepmc   +1 more source

Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR‐SB Utilizing Semi‐Mechanistic Model

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Lecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to protofibrils of amyloid‐beta (Aβ) protein. In clinical studies, lecanemab has been shown to reduce amyloid markers in early symptomatic Alzheimer's disease and slow decline on clinical endpoints of cognition and function.
Pratik Bhagunde   +7 more
wiley   +1 more source

Deciphering the Transcriptomic Signatures of Aging Across Organs in Mice

open access: yesAging Cell, Volume 25, Issue 2, February 2026.
Comprehensive transcriptomic profiling of eight mouse organs across six ages reveals how aging reshapes biological processes. Trajectory and network analyses distinguish shared and organ‐specific signatures, charting the molecular landscape of systemic aging.
Sarah Morsy   +9 more
wiley   +1 more source

Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study)

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 906-913, February 2026.
Abstract Aims To evaluate the lipid‐lowering efficacy, safety, and adherence of switching from moderate‐ or low‐intensity statin monotherapy to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus (T2DM) and dyslipidaemia.
Sangmo Hong   +10 more
wiley   +1 more source

Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease. [PDF]

open access: yesAlzheimers Dement
Pineda-Lopez L   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy